First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Completed · Phase 1, Phase 2 · NCT04083534
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
At a glance
- Research payments reported, 2025
- $284,506
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 43
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN5459 (drug)
- Dates
- Started 2019-09-26; completion 2025-05-01
- Results posted
- Not yet
In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit. In the phase 2 portion of the study, the primary objective is to assess the preliminary anti-tumor activity of REGN5459 as measured by objective response rate (ORR). In the phase 1 and phase 2 portion, the secondary objectives of the study are: * To assess the preliminary anti-tumor activity of REGN5459 as mea…
From ClinicalTrials.gov, last updated 2026-05-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $284,506 in research payments for this study in 2025 (37 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Attaya Suvannasankha, M.D. Hematology & Oncology · Indianapolis, IN
- Matthew J. Pianko, M.D. Hematology · Ann Arbor, MI
- Prashant Kapoor, MD Hematology · Rochester, MN
- Joshua R. Richter, M.D. Medical Oncology · New York, NY
- Larry D. Anderson JR., M.D. , PHD Medical Oncology · Dallas, TX
- Christine Ye Physical Therapy Assistant · Vancouver, WA
- Anita D'souza, MD Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic $151,914
- Medical College of Wisconsin PArkinsons Program $36,342
- Ut MD Anderson Cancer Center $33,519
- Icahn School of Medicine at Mount Sinai $32,260
- Indiana University $18,250
- University of Michigan Health System, MI $12,052
- The University of Texas Southwestern Medical Center $169
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.